Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up Following Analyst Upgrade

Enliven Therapeutics, Inc. (NASDAQ:ELVN) gapped up prior to trading on Wednesday after HC Wainwright raised their price target on the stock from $48.00 to $56.00. The stock had previously closed at $31.15, but opened at $33.76. HC Wainwright currently has a buy rating on the stock. Enliven Therapeutics shares last traded at $35.7160, with a volume of 2,626,280 shares changing hands.

Several other research firms have also commented on ELVN. Wall Street Zen lowered shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Mizuho upped their target price on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, January 21st. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $43.40.

Insider Buying and Selling

In other news, COO Anish Patel sold 48,300 shares of the business’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.99, for a total transaction of $1,351,917.00. Following the completion of the transaction, the chief operating officer directly owned 215,011 shares of the company’s stock, valued at approximately $6,018,157.89. The trade was a 18.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Joseph P. Lyssikatos sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $29.04, for a total transaction of $145,200.00. Following the sale, the insider owned 740,188 shares in the company, valued at $21,495,059.52. The trade was a 0.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 232,180 shares of company stock worth $6,217,033 in the last quarter. Company insiders own 25.90% of the company’s stock.

More Enliven Therapeutics News

Here are the key news stories impacting Enliven Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target to $56 and maintained a Buy rating, implying sizable upside versus recent levels — a clear catalyst for investor demand. HC Wainwright raises PT to $56 (Benzinga)
• Positive Sentiment: Mizuho boosted its target to $45 and set an Outperform rating, reinforcing the analyst upgrade momentum and providing additional institutional validation. Mizuho raises PT to $45 (Benzinga)
• Positive Sentiment: Merck’s $6.7B acquisition of Terns lifted sentiment across the oncology group and directly benefited Enliven by highlighting the value of blood-cancer programs, which helped spark a large intraday jump in ELVN shares. Merck buys Terns — ELVN share reaction (MSN)
• Positive Sentiment: Coverage notes that ELVN has hit new multi‑year and 52‑week highs as analysts turn upbeat, which can attract momentum and crossover buying from funds tracking breakouts. ELVN hits 52-week high (American Banking News)
• Neutral Sentiment: Several media outlets and aggregator posts are amplifying the price-target changes and deal-driven optimism; this increases visibility but doesn’t change fundamentals immediately. Coverage roundup (Kalkine Media)

Institutional Investors Weigh In On Enliven Therapeutics

A number of large investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in Enliven Therapeutics in the fourth quarter valued at $83,000. Quantbot Technologies LP increased its holdings in Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after buying an additional 1,434 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Enliven Therapeutics in the fourth quarter valued at $95,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Trading Up 10.6%

The company has a market capitalization of $2.35 billion, a PE ratio of -21.12 and a beta of 0.33. The stock has a fifty day simple moving average of $28.32 and a 200-day simple moving average of $22.84.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.06). As a group, equities research analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.